Despite the great advances that have been made in the treatment of both adult and childhood acute lymphoblastic leukaemia, there are still approximately one half of all adults and one third of all children who relapse during or following the cessation of treatment (Chessells, 1987) . The prognosis for these patients who continue with further conventional chemotherapy following relapse is poor (Champlin & Gale, 1989 ). The main current therapeutic strategy for patients with relapsed acute leukaemia that have failed primary treatment, is very high dose ablative chemo-radiotherapy followed by allogeneic or autologous bone marrow transplantation (Report from the Working Party on Leukaemia, 1988) . Allogeneic transplantation offers a considerably higher success rate in terms of cure than autografting but HLA matched donors are available to only a small minority in need of a transplant (Kersey et al., 1987) . The challenge therefore is to devise alternative therapies which will prove effective for those patients who do relapse and which might also prove beneficial as a compliment to conventional treatment, improving the overall cure rate and reducing the toxicity of treatment overall. Targeted therapy utilising monoclonal antibodies for selectivity delivering drugs, toxins or radioisotopes to target tumour cells offers one possible alternative method for the elimination of residual neoplastic cells.
Immunotoxins (IT) are hybrid molecules comprised of a toxin species covalently coupled, usually through a cleavable thiol bond to an antibody (Hertler & Frankel, 1989) . The antibody confers target cell specificity on the toxin and provides the means for entry of the toxin into the cell following internalisation of the IT by endocytotis (Press et al., 1988) . The subsequent cleavage of the toxin species from the antibody and its route of translocation from the endosome compartment to target ribosomes in the cytosol all act to influence the efficacy of any particular IT. IT's have proven highly effective at selectively killing a variety of target tumours cells in vitro (Bregni et al., 1989; Ghetie et al., 1988; Strong et al., 1985) and in vivo (Blythman et al., 1986; Thorpe et al., 1985; FitzGerald et al., 1986) ) and clinical trials of IT's for a variety of malignant neoplasias are now underway (Spitler, 1988; Laurent et al., 1988; Byers et al., 1990) . A number of major obstacles need to be overcome before IT-type treatments make any major impact in the clinical treatment of cancer. Problems exist regarding the slow rate with which IT's kill target cells (Casellas et al., 1984) and linked to this is the short half life of IT conjugates in vivo (Scott et al., 1987) , though with regard to the latter recent improvements in coupling chemistry has led to a prolongation of in vivo half life of IT's constructed with Ricin A chain . Fortuitously, IT's constructed with saporin have an apparent longer half life in vivo in the mouse (Blakey et al., 1988) , though saporin IT's appear to be up to 30 times more toxic than ricin A chain IT's for liver parenchyma. Strategies need to be developed to overcome these and similar types of problem which will be arrived at only by careful and meticulous study of both the in vitro and in vivo properties and characteristics of IT's or BsAb's.
As an alternative to conventional IT's some workers have constructed bispecific antibodies with dual specificities for a tumour associated target molecule in one of the Fab arms and for a toxin in the other (Webb et al., 1985; Glennie et al., 1988) . The major advantage here is that chemical procedures for coupling the toxin to the antibody are no longer required and that the BsAb may be administered and allowed to localise to the tumour cell surface prior to administration of toxin, a strategy that may serve to reduce the immunogenicity and perhaps also the toxicity of the complex. We describe here the characteristics and performance of the BsAb HB2 x DB7-18 for delivering the ribosome inactivating protein (rip) saporin to the T-ALL cell line HSB-2 via the CD7 cell surface molecule. We demonstrate that this BsAb is probably just as effective as an IT for selectively delivering a cytotoxic dose of saporin to this T-ALL cell line.
Materials and methods
Human acute leukaemia cell lines Three established human acute leukaemia cell lines were used for the purposes of this study, the CD7+ T-ALL cell line HSB-2, the CD7-promyelocytic leukaemia cell line HL60 and the CD7 weakly positive T-ALL cell line HPB-ALL. All three cell lines were maintained in the logarithmic phase of growth in RPMI 1640 medium supplemented with 10% foetal calf serum (Gibco), 1 mmol glutamine, I mmol sodium pyruvate, 100 IU ml-' benzyl penicillin and 100 lg ml-' streptomycin sulphate. Cells were only used when the cell viability of the cultures exceeded 95%.
Saporin
The ribosome inactivating protein (rip) Saporin was purified from the seeds of Saponaria officinalis as previously described (Stirpe et al., 1983) . SDS-polyacrylamide gel electrophoresis of the final preparation revealed a single band with an M, corresponding to 29,500 daltons. The concentration of saporin was estimated from its absorbance at 280 nmol taking Alcm280 as equal to 0.6.
Monoclonal antibodies
The anti-saporin MoAb DB7-18 (Glennie et al., 1987) and the anti-CD7 MoAb HB2 were used in this study. Hybridoma cells secreting each of these antibodies were injected into pristane primed mice for the production of antibody containing ascitic fluids. The 7S IgG fractions of ascitic fluid were isolated by precipitation with 2 M ammonium sulphate followed by ion exchange chromatography on Trisacryl-M-DEAE. F(ab')2 fragments for each MoAb were prepared by limited proteolysis with pepsin at pH 4.2 as described previously (Glennie et al., 1988 Kinetic studies The kinetics of protein synthesis inactivation by BsAb and saporin was determined in 96 well microcultures of HSB-2 cells exposed to a various concentrations of saporin (range 10-11 to 10-7M) together with BsAb at 0.1 g ml1'. HSB-2 cells were incubated for 2 h in supplemented leucine-free RPMI medium at 37°C and then triplicate samples of 1 x 105 cells added to wells of a 96 well microculture plate containing each appropriate concentration of saporin and BsAb in supplemented leucine-free RPMI. Microculture plates were maintained at 37C in a humidified atmosphere of 5% CO2 in air and at 2, 6, 12, 24 and 48 h 1.0 I&Ci 3H-leucine was added to each well of the appropriate cultures and cells harvested after a 1 h pulse onto glassfibre mats as described above. Regression analysis of 3H-leucine incorporation levels (expressed as a percentage of control cultures) vs each timepoint studied was undertaken for each saporin concentration employed. The time taken to reduce the protein synthesis level of HSB-2 cells by one log is defined as the t1o and was obtained from the intercept point of the regression line with the 10% level on the regression chart.
Long term HSB-2 cultures 1 x 105 HSB-2 cells were continuously exposed to various concentrations of saporin and BsAb in supplemented RPMI medium in 25 cm3 tissue culture flasks maintained at 37°C in a humidified atmosphere of 5% CO2 in air. Daily viable cell counts were undertaken for a 1O day period and 3H-leucine incorporation estimated as described above in parallel 96 well microcultures of HSB-2 cells exposed in triplicate to the same concentrations of BsAb and saporin.
Results
Cell surface expression of CD7 by HSB-2, HPB-ALL and HL60 cells Flow cytometry revealed that 98% of HSB-2 cells expressed CD7 strongly with a mean fluorescent intensity of 259 (arbitrary units). Ninety five per cent of HPB-ALL cells were effectively negative or very weakly positive for CD7 expression but a subpopulation of < 5% of the cells showed moderate expression with a mean fluorescent intensity within this population of 63 arbitrary units. All HL60 cells were effectively negative for CD7 expression with a mean fluorescent intensity of only 8.3 arbitrary units.
Specific delivery of saporin to the CD7+ cell line HSB-2 by BsAb
The F(ab'7y)2 BsAb HB2 x DB7-18 with anti-CD7 specificity in one Fab arm and anti-saporin specificity in the other arm was constructed in order to investigate its effectiveness at specifically delivering a lethal amount of saporin to the CD7+ T-ALL cell line, HSB-2. The CD7-promyelocytic cell line HL60 and the weakly positive T-ALL cell line HPB-ALL were used as a check of target cell specificity in related experiments. All results reported here are representative of each experiment repeated on at least three separate occasions.
Bispecific antibody and saporin titration against HSB-2 cells Triplicate cultures of 1 x 105 HSB-2 cells were exposed for 48 h to BsAb at 0.1 yg ml-' together with increasing concentrations of saporin (ranging from 10-12 to 1O6 M). Identical numbers of cells were exposed to concentrations of saporin alone or saporin + an equimolar mixture of the two different F(ab')2 fragments (0.05 jLg m1' of each) from which the Kinetics of BsAb action Experiments were conducted to determine the rate at which various concentrations of saporin (range 10-11 to 10-7M) inactivated protein synthesis in HSB-2 cells in the presence of BsAb at 0.1 Lg ml-'. Figure 3 shows the regression analysis for the rate of protein synthesis inactivation for each saporin concentration (expressed as the log percentage control 3H-leucine incorporation vs time). The rate of inactivation is clearly concentration dependent and linear in nature. Regression coefficients obtained for each saporin concentration were r = 0.908 (10-7 M), 0.912 (10-8M), 0.983 (10-9 M), 0.831 (10--0 M) and 0.610 (10-" M). The time taken for a one log inhibition of protein synthesis relative to an equivalent number of untreated control cells is defined as the t,o and is calculated from the intercept point of the regression line with the 10% level on the chart, and this value, plotted against each saporin concentration is shown in a Figure 3a graph. At a saporin concentration 10-" M no observable inhibition of protein synthesis was detectable and the t,o value is therefore infinitely long and consequently unplottable on the graph. At a saporin concentration of 10-°M the t,o was shown to be 226 h whilst at saporin concentrations of 10-9, 10-8 and 10-7 M the tjo values were shown to be 46, 30 and 20 h, respectively. In a second type of specificity experiment we attempted to block the binding of BsAb to the CD7 target molecule on the HSB-2 cell surface with a 10-fold excess of HB2 F(ab')2. As in previous titration experiments HSB-2 cells were exposed to saporin alone (ranging from l1o-2 to 10-6 M) or in combination with BsAb (0.1 iLg ml-') in the absence and presence of a 10-fold excess of HB2 F(ab')2 (1 iLg ml-') and 3H-leucine incorporation evaluated after a 48 h exposure. The results in Figure 5 show clearly that F(ab')2 shifted the titration curve to the right, significantly reducing the cytotoxicity of the BsAb from an IC" of 0.22 nmol without F(ab')2 to 73 nmol with F(ab')2 a 332-fold decrease in toxicity demonstrating effective blocking of BsAb binding by F(ab')2.
Effects of BsAb and saporin on long term cultures of HSB-2 cells A series of experiments was undertaken to establish the effects of various concentrations of saporin and BsAb on HSB-2 cell proliferation and protein synthesis in cell culture measured daily over a 1O day period.
In the first set of experiments cultures of cells were continuously exposed to a fixed BsAb concentration of 0.1 Lg ml-' in the presence of varying concentrations of saporin ranging from 0.000001 lg ml-' (0.33 pmol) to 0.1 ILg ml-' (3.3 nmol) and daily cell counts and 3H-leucine incorporations determined over a 10day period. correlation between the viable cell count data ( Figure 6a ) and leucine incorporation data (Figure 6b ). The dose response to saporin concentration in the presence of a fixed BsAb concentration of 0.1 tg ml-' is clearly obvious with 0.01 g ml-' of saporin giving complete and total inhibition of both cell division and leucine incorporation. Microscopic examination at 10 days revealed that the vast majority of cells in these cultures were non-viable with very rare, apparently viable cells occasionally visible in the culture. At a saporin concentration of 0.001 yg ml-' cell division was slowed to approximately two thirds that obtained with untreated control HSB-2 cultures whilst leucine incorporation was reduced to less than half that seen in the control cultures. Saporin concentrations of 0.0001 jg m'l (3.3 pmol) or less had little or no effect.
In similar experiments we continuously exposed cultures of HSB-2 cells to saporin at two fixed concentrations of 0.1 tg ml-' (3.3 nmol) (Figures 7a and b) or 0.01 g ml-' (0.33 nmol) (Figures 7c and d there being an extremely good correlation between viable cell count and leucine incorporation over the range of BsAb concentrations used. Thus, BsAb used at 0.01 and 0.1 tg ml-' was effective at totally inhibiting HSB-2 cell division and protein synthesis at a saporin concentration of 0.1 ag ml-1 whilst cells treated with 0.005 gg ml-' BsAb showed a shallower reduction and cell proliferation and protein synthesis began to increase once again by day 9 (Figures   7a and b) . At a BsAb concentration of 0.001 fg ml-' viable cell count and protein synthesis levels dropped to a nadir by day 5 but began to recover thereafter achieving control levels by day 8. ) to repeat a further round of treatment with the same levels of BsAb and saporin. Once HSB-2 cells surviving this second round of treatment, began dividing again, they were washed, put into fresh complete RPMI medium and grown to high density prior to investigation. These twice treated HSB-2 cells were designated HSB-2(G +). Prior to study HSB-2(G +) and untreated HSB-2 cells were analysed by flow cytometry for cell surface CD7 expression using the native anti-CD7 MoAb HB2. There were no observed differences in the level of cell surface expresson of CD7 between the native HSB-2 cells and HSB-2(G +) cells (data not shown). HSB-2(G +) cells were exposed for 48 h to increasing concentrations of saporin (range 10-12 to 10-6 M) together with BsAb (0.1 g ml-') and 3H-leucine incorporation evaluated.
HSB-2(G +) cells were still found to be sensitive to BsAb/ 
Discussion
The present study has clearly shown that a F(ab'y)2 bispecific antibody (BsAb) with dual anti-CD7 and anti-saporin specificities can effectively and specifically deliver a cytotoxic dose of saporin to the CD7+ T-ALL cell line HSB-2. The cytotoxic response following BsAb-mediated delivery of saporin to HSB-2 cells was dose dependent in terms of both BsAb and saporin concentrations. We were also able to demonstrate a very good correlation between BsAb/saporinmediated inhibition of cell proliferation and inhibition of protein synthesis in 10 day cell cultures and moreover observe that cell death was actually occurring in these cultures.
CD7 has been successfully used as the target molecule on a variety of fresh and established human leukaemia cell lines for targeting intact ricin (Strong et al., 1985) , ricin A chain (Myers et al., 1984) and single chain ribosome inactivating proteins (rip) (Ramakrishnan & Houston, 1984 ). An immunotoxin constructed with the anti-CD7 MoAb 3A1 and the rip pokeweed antiviral protein (PAP) was highly cytotoxic for the T-ALL cell line HSB-2 with an observed IC50 of 0.11 nmol (Ramakrishnan & Houston, 1984 Saporin is a single chain ribosome inactivating protein (Stirpe et al., 1983) (Laurent et al., 1986 ).
The observation that HSB-2(G +) cells that had been put through two cycles of BsAb and saporin treatment were equally as sensitive as previously untreated HSB-2 cells, to subsequent rounds of BsAb/saporin treatment provides an important clue as to how these cells escaped destruction in the first instance. There were no observed differences between HSB-2(G +) and HSB-2 cells for cell surface expression of CD7 showing that a subpopulation of variant target antigen negative cells had not been selected for by BsAb/saporin treatment. This is unlike the findings of Glennie et al. (1988) where target guinea pig L2C tumour cells emerging following BsAb/saporin treatment in vivo were target antigen negative.
Similarly, a transferrin-Ricin A chain resistant clone of the T-cell line CEM had reduced levels of expression of the target transferrin receptor molecule (CD71) (Raso & Basala, 1984) though it has not always been possible to correlate sensitivity to an immunotoxin and the level of expression of the target antigen by the target cell (Goldmacher et al., 1987) . The retained sensitivity of HSB-2(G +) cells to BsAb/ saporin also excludes the possibility that we had selected for a subpopulation of HSB-2 cells with an inherent defect in endocytosis transport of BsAb-saporin complexes across the membrane (Goldmacher et al., 1987) , or with endosomecytosol translocation of toxin to the target ribosome. We feel that the most likely explanation is quite simply that a small proportion of the original HSB-2 cells at the time of BsAb/ saporin treatment were negative or weakly positive for CD7 expression and therefore escaped lethal intoxication at this time. Following their subsequent outgrowth some weeks later, by which time the majority of the BsAb/saporin had been consumed or had degraded in culture, these cells then upregulated their CD7 expression and were therefore accessible to saporin delivery with the BsAb when so treated on a future occasion. This likely possibility really underlines the potential shortcomings of toxin delivery via a single target molecule and argues strongly for using multiple target molecules for toxin delivery, firstly to overcome the heterogeneity of target molecule expression within a tumour cell population and secondly to deliver greater amounts of toxin to those tumour cells that are positive for all target molecules.
IT's have been used for the ex vivo purging of residual leukaemic blasts from bone marrow harvested from acute leukaemia patients in remission prior to autografting (Strong et al., 1985) . Autografting is a significantly less toxic procedure than allografting but is also less successful with the majority of patients relapsing post-transplant (Kersey et al., 1987) . Indications are that the graft vs host disease that often accompanies allogeneic transplantation provides an effective anti-leukaemia response (graft vs leukaemia) that serves to eliminate residual leukaemic blasts within the patient (Butturini et al., 1987) . It is this particular effect, absent in autologous transplantation, that might be partially, if not wholly responsible for the lower success rate of autografting. In view of the high toxicity of the allografting procedure and the limited availability of matched donors, methods for improving the success rate in autografting would represent a major step forward in the treatment of relapsed disease. It is not clear whether the relapses that occur following autografting do so from residual leukaemic stem cells remaining in the patient or in the reinfused marrow inoculum. In practice both may contribute and future objectives should aim to reduce residual tumour cell numbers to the absolute minimum achievable. Thus, in vivo administration of IT's during conditioning prior to transplant, for the elimination of residual disease in the patient combined with ex vivo treatment of the patients own harvested marrow prior to reinfusion may lead to some improvement. There is thus a strong case for developing IT type therapies for in vivo use and recently small clinical studies have been undertaken in leukaemia (Laurent et al., 1988; Byers et al., 1990 ) and other malignant tumour types (Spitler, 1988) .
The clinical utility of BsAb's for targeting toxins to unwanted neoplastic cells in vivo yet remains to be seriously explored. Glennie et al. (1988) have undertaken in vivo immunotherapy studies in guinea pigs bearing the guinea pig B-lineage acute lymphoblastic leukaemia tumour L2C, targeting saporin against an idiotypic determinant on the tumour cell surface with a BsAb. In these studies there was a significant prolongation of survival in animals receiving saporin and BsAb, the extent of which was determined by the route of administration and molar ratio of BsAb to saporin employed. It is essential that the behaviour and performance of BsAb's for delivering toxins to human leukaemia cells is thoroughly investigated in vivo in an animal xenograft model prior to any attempt to utilise them clinically. To this end we are actively developing a model of human acute leukaemia in severe combined immunodeficient (scid) mice (Kamel-Reid et al., 1989) with the objective of commencing immunotherapy trials with BsAb's in these animals in the very near future.
